Quantum BioPharma Cuts Costs, Advances Lucid-MS to Phase 2
Quantum BioPharma reports Q2 2026 results with 53% expense cut, $9.5M cash, and FDA IND approval for Lucid-MS Phase 2 trial in progressive MS.
This news matters because Quantum BioPharma's FDA approval for Lucid-MS Phase 2 trial represents a significant step toward a potential new treatment for progressive multiple sclerosis, a condition with limited therapeutic options. The company's improved financial health and reduced burn rate increase its ability to fund critical clinical development, potentially impacting patients' lives and the biotech investment landscape.